Fluorochrome conjugated antibodies to following human antigens were used for flow cytometric analysis of
KEAP1 edited cells: TCR-BV421(BioLegend, San Diego, CA),
CD4-PerCP-Cy5.5 (BD Biosciences, Franklin Lakes, NJ),
CD8-APC (BioLegend, San Diego, CA),
CD25-BV605 (eBioscience, San Diego, CA),
FoxP3-APC (eBioscience, San Diego, CA), or
Alexa488 (BioLegend, San Diego, CA)
CD69-APC-Cy7 (BD Biosciences, Franklin Lakes, NJ),
IFNγ-PE (BD Biosciences, Franklin Lakes, NJ),
TNFα-FITC (BD Biosciences, Franklin Lakes, NJ),
IL4-AlexaFluor 488 (BioLegend, San Diego, CA) IL-10-PE or APC (eBioscience, San Diego, CA), and IL17-BV421 or PE (BioLegend, San Diego, CA). T lymphocytes (~5×10
5) were stimulated with
leukocyte activation cocktail (BD Pharmigen, San Jose, CA) containing PMA (Phorbol 12-Myristate 13-Acetate), ionomycin and brefeldin A before staining for surface markers and intracellular cytokines. Labelled samples were analyzed with
LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ). Unstained and unstimulated samples were used to correctly identify and gate cell populations during analysis using FlowJo software (Tree Star Inc., Ashland, OR).
Noel S., Lee S.A., Sadasivam M., Hamad A.R, & Rabb H. (2018). KEAP1 editing using CRISPR/Cas9 for therapeutic NRF2 activation in primary human T lymphocytes. Journal of immunology (Baltimore, Md. : 1950), 200(5), 1929-1936.